sabato, 2 maggio 2026

Notizie AIOM – anno XVIII

FDA Approval Sought for Liso-Cel in Large B-Cell Lymphoma

December 18, 2019 - Bristol-Myers Squibb has submitted a biologics license application (BLA) to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma ...
Leggi tutto

FDA approves new type of therapy to treat advanced urothelial cancer

December 18, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to Enfortumab vedotin-ejfv, a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells - in this case, the cell adhesion ...
Leggi tutto

FDA Approval Sought for Tazemetostat in Follicular Lymphoma

December 19, 2019 - A new drug application (NDA) has been submitted to the FDA for tazemetostat as a treatment for patients with relapsed/refractory follicular lymphoma, with or without EZH2 activating mutations, who have received ≥2 prior lines of systemic therapy. ...
Leggi tutto

FDA Grants Priority Review to UGN-101 for Urothelial Cancer

December 19, 2019 - The FDA has granted a priority review designation to a new drug application (NDA) for UGN-101 (mitomycin gel) for the treatment of patients with low-grade, upper tract urothelial cancer (UTUC). The designation is based on results from the pivotal phase ...
Leggi tutto

FDA Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 20, 2019 - The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki (DS-8201) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in ...
Leggi tutto

FDA Approval Sought for Tucatinib in HER2+ Breast Cancer

December 23, 2019 - Seattle Genetics, Inc., has submitted a new drug application (NDA) to the FDA for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, ...
Leggi tutto

FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma

December 23, 2019 - The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma. Currently, the agent is being evaluated in an ongoing, open-label, nonrandomized ...
Leggi tutto

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30, 2019 - Richard Pazdur, MD, a 2019 winner of the OncLive® Giants of Cancer Care® award for community outreach, education, and cancer policy, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs ...
Leggi tutto

FDA Approves Olaparib for Frontline Maintenance in Pancreatic Cancer

December 30, 2019 - The FDA has approved the PARP inhibitor olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy ...
Leggi tutto

Adjuvant T-DM1 Approved in Europe for HER2+ Early Breast Cancer

December 19, 2019 - The European Commission has approved ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based ...
Leggi tutto